PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models

BACKGROUND: The MET receptor tyrosine kinase represents a promising target in cancer. PIK3CA activating mutations are common in several tumor types and can potentially confer resistance to anti-receptor tyrosine kinase therapy. METHODS: MET and/or PI3K pathway inhibition was assessed in NIH3T3 cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Nisa, Lluís, Häfliger, Pascal, Poliaková, Michaela, Giger, Roland, Francica, Paola, Aebersold, Daniel Matthias, Charles, Roch-Philippe, Zimmer, Yitzhak, Medová, Michaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441085/
https://www.ncbi.nlm.nih.gov/pubmed/28532501
http://dx.doi.org/10.1186/s12943-017-0660-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441085/
https://www.ncbi.nlm.nih.gov/pubmed/28532501
http://dx.doi.org/10.1186/s12943-017-0660-5

Ejemplares similares